Corporate News Overview
Karyopharm Therapeutics (KPTI) – Recent Performance and Regulatory Update
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) experienced a notable intra‑day rally, trading up 28.77 % during the 24‑hour period that concluded at 04:59 PM Central Europe on Friday, 23 October 2026. At the time of writing, a single share of KPTI is available on major exchanges for approximately USD 0.46. The company’s market capitalization stands at USD 9.6 million, supported by a circulating supply of 22.5 million shares. Over the last 24 hours, roughly USD 4.1 million worth of shares were exchanged.
Despite the recent surge, KPTI’s price trajectory has been largely downward when viewed on a longer time horizon. Since the close of the previous month, the stock has fallen 68.8 %. The 200‑day simple moving average (SMA) currently sits at USD 6.26, well above the present trading level, underscoring a bearish trend. Historically, KPTI’s price has ranged from a low of USD 0.31 on 15 October 2026 to a high of USD 10.99 on 24 February 2026, reflecting significant volatility typical of early‑stage biopharmaceutical companies.
Recent Filing: Extension of Forbearance Agreement
On 22 October 2026, Karyopharm Therapeutics filed a Current Report (Form 8‑K) announcing the extension of its existing Forbearance Agreement. Originally established on 10 September 2026, the agreement was renewed on the filing date, shifting the deadline from the close of business on 22 October to the close of business on 1 November. The filing confirms that the forbearance period has been extended in line with contractual terms and reports no additional material events.
Comparative Performance of Peer Stocks
The performance of several peers in the biotechnology sector over the preceding 24 hours is summarized below:
| Company | Ticker | 24‑hour Change | Current Price | Market Capitalization |
|---|---|---|---|---|
| Lisata Therapeutics | LSTA | –3.81 % | USD 1.00 | USD 11.3 million |
| Gt Biopharma | GTBP | +2.03 % | USD 5.35 | USD 11.2 million |
| Alaunos Therapeutics | TCRT | –1.30 % | USD 2.43 | USD 11.1 million |
| Passage Bio | PASG | –0.28 % | USD 3.48 | USD 11.6 million |
Notable Developments – Alaunos Therapeutics
Alaunos Therapeutics (TCRT) filed a Current Report on 21 October 2026 in response to a Nasdaq delisting notice. The company had been non‑compliant with the Nasdaq Stockholders’ Equity Requirement following a reporting of equity below the mandated threshold. Alaunos addressed the issue by completing a substantial financing transaction and merging with Velaris Therapeutics, thereby increasing its equity base. The company also secured a waiver of a cash settlement right for a portion of its newly issued preferred shares, further reinforcing its balance sheet. Nasdaq has scheduled a hearing for 10 November 2026 to evaluate Alaunos’s compliance status. The company anticipates that the hearing will be cancelled if Nasdaq confirms full compliance.
Company Profile – Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a publicly traded, oncology‑focused pharmaceutical company operating within the health care and biotechnology sectors. The company develops combination therapies incorporating dexamethasone for patients with pretreated multiple myeloma and offers both single‑agent and combination treatments against a broad spectrum of human cancers. Karyopharm’s therapeutic portfolio serves patients across the United States, Germany, and Israel. The company first entered the Nasdaq market on 6 November 2013 and maintains its corporate website at www.karyopharm.com .
